Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Antigens, CD20/immunology"'
Autor:
Daniela Wesch, Matthias Peipp, Andreas Humpe, J.G.J. van de Winkel, P. W. Parren, Dieter Kabelitz, Anja Muskulus, Renate Burger, Christian Kellner, Sebastian Lutz, Martin Gramatzki, Hans-Heinrich Oberg
Publikováno v:
Peipp, M, Wesch, D, Oberg, H H, Lutz, S, Muskulus, A, van de Winkel, J G J, Parren, P W H I, Burger, R, Humpe, A, Kabelitz, D, Gramatzki, M & Kellner, C 2017, ' CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells ', Scandinavian Journal of Immunology, vol. 86, no. 4, pp. 196-206 . https://doi.org/10.1111/sji.12581
Human γδ T cells are innate-like T cells which are able to kill a broad range of tumor cells and thus may have potential for cancer immunotherapy. The activating receptor natural killer group 2 member D (NKG2D) plays a key role in regulating immune
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::446e5c0ed34b1f93fde1e38c1796209d
https://pubmed.ncbi.nlm.nih.gov/28708284
https://pubmed.ncbi.nlm.nih.gov/28708284
Autor:
Gilles Salles, Charlène Niogret, Abdel Aouacheria, Romain Jugé, Aurélie Cornut-Thibaut, Wei Wen Chien, Loïc Lionnard, Ariel Savina, Jérôme Kucharczak
Publikováno v:
Leukemia Research
Leukemia Research, Elsevier, 2017, 55 (2), pp.41-48. ⟨10.1016/j.leukres.2017.01.010⟩
Leukemia Research, 2017, 55 (2), pp.41-48. ⟨10.1016/j.leukres.2017.01.010⟩
Leukemia Research, Elsevier, 2017, 55 (2), pp.41-48. ⟨10.1016/j.leukres.2017.01.010⟩
Leukemia Research, 2017, 55 (2), pp.41-48. ⟨10.1016/j.leukres.2017.01.010⟩
International audience; GA101, also known as obinutuzumab or Gazyva (Gazyvaro), is a glycoengineered type II humanized antibody that targets the CD20 antigen expressed at the surface of B-cells. This novel anti-CD20 antibody is currently assessed in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::778241a2c47e90356b8a185492faa748
https://hal.archives-ouvertes.fr/hal-02355692/document
https://hal.archives-ouvertes.fr/hal-02355692/document
Autor:
Martino Introna, Paul W. H. I. Parren, Fabio Da Roit, Alessandro Rambaldi, Ronald P. Taylor, Giuseppe Gritti, Josée Golay, Frank J. Beurskens, Esther C.W. Breij, Patrick J. Engelberts
Publikováno v:
Da Roit, F, Engelberts, P J, Taylor, R P, Breij, E C, Gritti, G, Rambaldi, A, Introna, M, Parren, P W, Beurskens, F J & Golay, J 2015, ' Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy ', Haematologica, vol. 100, no. 1, pp. 77-86 . https://doi.org/10.3324/haematol.2014.107011
The novel Bruton tyrosine kinase inhibitor ibrutinib and phosphatidyl-4-5-biphosphate 3-kinase-δ inhibitor idelalisib are promising drugs for the treatment of chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma, either alone or in combinati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb00af48e71c6ed89103d123792d3918
https://doi.org/10.3324/haematol.2014.107011
https://doi.org/10.3324/haematol.2014.107011
Autor:
Paul W. H. I. Parren, Marleen Voorhorst, Patrick J. Engelberts, Tom Vink, Frank J. Beurskens, Thomas Valerius, Wendy J.M. Mackus, Joost M. Bakker, Stefanie Derer, Tom van Meerten, Esther C.W. Breij, Janine Schuurman, Jan G. J. van de Winkel
Publikováno v:
Engelberts, P J, Voorhorst, M, Schuurman, J, Van Meerten, T, Bakker, J M, Vink, T, Mackus, W J M, Breij, E C W, Derer, S, Valerius, T, van de Winkel, J G J, Parren, P W H I & Beurskens, F J 2016, ' Type i CD20 antibodies recruit the B cell receptor for complement-dependent lysis of malignant B cells ', Journal of Immunology, vol. 197, no. 12, pp. 4829-4837 . https://doi.org/10.4049/jimmunol.1600811
Journal of Immunology, 197(12), 4829-4837. AMER ASSOC IMMUNOLOGISTS
Journal of Immunology, 197(12), 4829-4837. AMER ASSOC IMMUNOLOGISTS
Human IgG1 type I CD20 Abs, such as rituximab and ofatumumab (OFA), efficiently induce complement-dependent cytotoxicity (CDC) of CD20+ B cells by binding of C1 to hexamerized Fc domains. Unexpectedly, we found that type I CD20 Ab F(ab')2 fragments,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4d9197ec28f899d5e6a016465f31efa
https://portal.findresearcher.sdu.dk/da/publications/34aca668-9af2-49ed-945c-3a69d108b381
https://portal.findresearcher.sdu.dk/da/publications/34aca668-9af2-49ed-945c-3a69d108b381
Autor:
Anastasia Pantelias, Ming Kuan Chyan, Yukang Lin, Donald K. Hamlin, Oliver W. Press, John M. Pagel, Jaideep Shenoi, Feng Wan, Steven I. Park, Shani M. Wilbur, D. Scott Wilbur, Franz Buchegger
Publikováno v:
Bioconjugate Chemistry, Vol. 21, No 7 (2010) pp. 1225-1238
Previous studies have shown that pretargeting protocols, using cancer-targeting fusion proteins, composed of 4 anti-CD20 single chain Fv (scFv) fragments and streptavidin (scFv(4)-SAv), followed by a biotinylated dendrimeric N-acetyl-galactosamine bl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::957b9ef90d091395770121e5f33c8f61
https://doi.org/10.1021/bc100030q
https://doi.org/10.1021/bc100030q
Autor:
Finckh, A, Ciurea, A, Brulhart, L, Möller, B, Walker, U A, Courvoisier, D, Kyburz, D, Dudler, J, Gabay, C, Arthritis, on the behalf of the doctors of the Swiss Clinical Quality Management Programme for Rheumatoid
Publikováno v:
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, Vol. 69, No 2 (2010) pp. 387-393
Annals of the Rheumatic Diseases, vol. 69, no. 2, pp. 387-393
Annals of the Rheumatic Diseases, Vol. 69, No 2 (2010) pp. 387-393
Annals of the Rheumatic Diseases, vol. 69, no. 2, pp. 387-393
Background:Patients with rheumatoid arthritis (RA) with an inadequate response to TNF antagonists (aTNFs) may switch to an alternative aTNF or start treatment from a different class of drugs, such as rituximab (RTX). It remains unclear in which clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94f28974e832631a8607224a893fc89a
http://europepmc.org/articles/PMC2800201
http://europepmc.org/articles/PMC2800201
Publikováno v:
International Journal of Pharmaceutics, Vol. 331, No 2 (2007) pp. 190-6
Two types of antibody-labeled nanoparticles (mAb-NPs) were prepared with the aim to achieve specific tumor targeting. Anti-HER2 and anti-CD20 monoclonal antibodies (mAb) were used as model ligands. Small poly(dl-lactic acid) nanoparticles (PLA NPs) w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc46f7a49e502ee5ad0abb222538797d
https://doi.org/10.1016/j.ijpharm.2006.12.002
https://doi.org/10.1016/j.ijpharm.2006.12.002
Publikováno v:
Bioconjugate Chemistry, Vol. 17, No 1 (2006) pp. 139-145
In this study, selective cancer cell targeting of biodegradable poly(lactic acid) (PLA) nanoparticles (NPs) has been investigated in vitro. SKOV-3 (HER2 positive) ovarian cancer and Daudi (CD20 positive) lymphoma cell targeting was mediated by anti-H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27f36833eb836328ce69fa6d82ab827e
https://doi.org/10.1021/bc050137k
https://doi.org/10.1021/bc050137k
Autor:
Laurence Boumsell, Jean-Pierre Mach, Franz Buchegger, Martino Introna, Josée Golay, Luca Bologna, Pierre-Alain André
Publikováno v:
Blood, Vol. 116, No 17 (2010) pp. 3372-3373; author reply 3373-3374
To the editor: Two groups have recently proposed that type II anti-CD20 monoclonal antibodies (mAbs) B1 (tositumomab) and GA101, as well as anti–HLA-DR antibody (L243), induce strong homotypic adhesion and direct cell death. They claim, on the basi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::995c914528c4bb59258c0b9af347bda6
https://archive-ouverte.unige.ch/unige:20970
https://archive-ouverte.unige.ch/unige:20970
Autor:
Alwayn, I P, Xu, Y, Basker, M, Wu, C, Buehler, Leo Hans, Lambrigts, D, Treter, S, Harper, D, Kitamura, H, Vitetta, E S, Abraham, S, Awwad, M, White-Scharf, M E, Sachs, D H, Thall, A, Cooper, D K
Publikováno v:
Xenotransplantation, Vol. 8, No 3 (2001) pp. 157-71
Anti-Galalpha1-3Gal antibodies (antialphaGal Ab) are a major barrier to clinical xenotransplantation as they are believed to initiate both hyperacute and acute humoral rejection. Extracorporeal immunoadsorption (EIA) with alphaGal oligosaccharide col
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::ebbf7b7d0e4a951404936435c3909976
https://pubmed.ncbi.nlm.nih.gov/11472623
https://pubmed.ncbi.nlm.nih.gov/11472623